Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (CTRI/2026/09/116796) titled 'A Study to Assess Changes in Thinking and Memory in Patients with Solid Tumors Receiving Cancer Treatment and to Evaluate Whether Memantine Can Help Reduce Cognitive Decline' on Sept. 1.
Study Type: Interventional
Study Design:
Single Arm Study Method of generating randomization sequence:Not Applicable Method of allocation concealment:Not Applicable Blinding and masking:Not Applicable
Primary Sponsor: ACTREC, TMC
Condition:
Health Condition 1: C801- Malignant (primary) neoplasm, unspecified
Intervention:
Intervention1: Memantine: Memantine will be started with 5 mg once daily for 1 week, 5 mg twice...